Q-omics provides the consensus-scored TRPM2-AS profile across patient tissues and cancer cell-line models. TRPM2-AS expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRPM2-AS is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, TRPM2-AS RNA expression shows 14,313 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, COAD, and THYM as cancer lineages where TRPM2-AS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPM2-AS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPM2-AS survival associations across molecular data types. TRPM2-AS RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPM2-AS RNA expression–survival associations across cancer types. High TRPM2-AS expression shows unfavorable associations in UVM and LGG, but favorable associations in UCEC, PAAD, THCA and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify UVM as the clearest survival context for TRPM2-AS RNA expression.
This table summarizes TRPM2-AS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRPM2-AS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPM2-AS shows higher tumor expression in COAD, BLCA, STAD, LUSC, HNSC and LUAD. The COAD box plot shows higher TRPM2-AS RNA expression in tumor versus normal tissue (log2 FC = +2.106, t-test p < 0.001).
This table shows molecular features associated with TRPM2-AS in patient tissues and cancer cell lines. In patient samples, TRPM2-AS shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
